Use of proton pump inhibitors: An exploration of the attitudes, knowledge and perceptions of general practitioners

Digestion

Volumn 72, Issue 4, 2005, Pages 212-218

  Raghunath, A S ^a   Hungin, A P S ^a   Cornford, C S ^a   Featherstone, V ^b  

^a DURHAM UNIVERSITY   (United Kingdom)

^b Wold Research Network Hull and East Yorkshire   (United Kingdom)

Author keywords

Gastroenterology; General practitioners; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; CIMETIDINE; PROTON PUMP INHIBITOR;

ADULT; AGE; ARTICLE; CONSERVATIVE TREATMENT; CONSTANT COMPARATIVE METHOD; CONSULTATION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM DISEASE; DRUG COST; DRUG USE; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HELICOBACTER PYLORI; HUMAN; INDIGESTION; INFORMATION PROCESSING; MALE; MEDICAL DECISION MAKING; MEDICAL ETHICS; NORMAL HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; TRAINING; WITHDRAWAL SYNDROME;

ADULT; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG; PROTON PUMPS;

EID: 29244438843     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089727     Document Type: Article

References (35)

1. Department of Health: Prescription Cost Analysis: England 2002. London, Department of Health, 2003.
2. Hungin AP, Rubin GP, O'Flanagan H: Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-453.
3. Shaheen N, Ransohoff DF: Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA 2002;287:1982-1986.
4. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
5. Dent J, Jones R, Kahrilas P, Talley NJ: Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-347.
6. National Institute for Clinical Excellence: Technology Appraisal No. 7: Guidance on the Use of Proton Pump Inhibitors in the Treatment of Dyspepsia. London, NICE, 2000.
7. Boath EH, Blenkinsopp A: The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med 1997;45:1571-1579.
8. Barbour RS: Using focus groups in general practice research. Fam Pract 1995;12:328-334.
9. Glaser BG, Strauss AL: The purpose and credibility of qualitative research. Nurs Res 1966;15:56-61.
10. Green J: Grounded theory and the constant comparative method. BMJ 1998;316:1064-1065.
11. QSR NUD*IST 4 and NUD*IST Vivo Software for Qualitative Data Analysis. Google Search: QSR.NUD.IST, 2005.
12. Carthy P, Harvey I, Brawn R, Watkins C: A study of factors associated with cost and variation in prescribing among GPs. Fam Pract 2000;17:36-41.
13. Mazza D, Russell SJ: Are GPs using clinical practice guidelines? Aust Fam Physician 2001;30:817-821.
14. Raghunath AS, Hungin APS: Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey (abstract). Gut 2004;53(suppl 111):24.
15. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al: Head-to-head comparison of H(2)-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005;11:4067-4077.
16. van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001;CD002095.
17. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, et al: Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999;319:550-553.
18. Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;CD003245.
19. NICE Guideline: Dyspepsia: Managing Dyspepsia in Adults in Primary Care. National Guideline Research and Development Unit, University of Newcastle upon Tyne, 2004.
20. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;CD002296.
21. Gill D, Sharpe M: Frequent consulters in general practice: a systematic review of studies of prevalence, associations and outcome. J Psychosom Res 1999;47:115-130.
22. Vedsted P, Fink P, Sorensen HT, Olesen F: Physical, mental and social factors associated with frequent attendance in Danish general practice. A population-based cross-sectional study. Soc Sci Med 2004;59:813-823.
23. Grime J, Pollock K, Blenkinsopp A: Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001;51:703-711.
24. Chan J, Hui RL, Szpakowski JL: Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population. Am J Manag Care 2004;10:433-441.
25. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A: Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;42:13-16.
26. Inadomi JM, McIntyre L, Bernard L, Fendrick AM: Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940-1944.
27. Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y: Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol 2005;20:1365-1370.
28. Galmiche JP, Letessier E, Scarpignato C: Treatment of gastro-oesophageal reflux disease in adults. BMJ 1998;316:1720-1723.
29. Vakil N: How valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005;22(suppl 1):64-69.
30. Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A, et al: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
31. Raghunath AS, Hungin AP, Childs S, Wooff D: The prevalence of Helicobacter pylori in gastro-oesophageal reflux disease: a systematic review. BMJ 2003;326:736-739.
32. Raghunath AS, Hungin AP, Wooff D, Childs S: Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733-744.
33. Wathen B, Dean T: An evaluation of the impact of NICE guidance on GP prescribing. Br J Gen Pract 2004;54:103-107.
34. Pollock K, Grime J: The cost and cost-effectiveness of PPIs - GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare. Eur J Gen Pract 2003;9:126-133, 140.
35. Delaney BC, Moayyedi P, Forman D: Initial management strategies for dyspepsia. Cochrane Database Syst Rev, 2003.